230 related articles for article (PubMed ID: 10738365)
1. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
[No Abstract] [Full Text] [Related]
2. Antiretroviral rounds. When success is a pain.
Bartlett JG; del Rio C
AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
[No Abstract] [Full Text] [Related]
3. Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
Spooner KM; Lane HC; Masur H
Clin Infect Dis; 1996 Jul; 23(1):15-27. PubMed ID: 8816123
[No Abstract] [Full Text] [Related]
4. Clinical trials group: two studies are now open to patients who qualify.
Craig K
HIV Clin; 2000; 12(1):5. PubMed ID: 11810862
[No Abstract] [Full Text] [Related]
5. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs.
Rockstroh JK; Theisen A; Kaiser R; Sauerbruch T; Spengler U
AIDS; 1998 May; 12(7):829-30. PubMed ID: 9619824
[No Abstract] [Full Text] [Related]
6. Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus-co-infected patient starting antiretroviral triple combination therapy.
Karras A; Rabian C; Zylberberg H; Hermine O; Duchatelle V; Durand F; Valla D; Viard JP
AIDS; 1998 May; 12(7):827-9. PubMed ID: 9619823
[No Abstract] [Full Text] [Related]
7. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
8. Buffalo hump: what the experts suggest.
Piliero PJ; McComsey GA
AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
[No Abstract] [Full Text] [Related]
9. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
10. Triple nuke therapy--results after one year.
TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
[No Abstract] [Full Text] [Related]
11. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy.
Zylberberg H; Pialoux G; Carnot F; Landau A; Bréchot C; Pol S
Clin Infect Dis; 1998 Nov; 27(5):1255-8. PubMed ID: 9827279
[TBL] [Abstract][Full Text] [Related]
12. Elvucitabine data released at CROI.
AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
Villalba N; Gómez-Cano M; Casas E; Soriano V; Valencia E; González-Lahoz J
AIDS; 1997 Dec; 11(15):1896-7. PubMed ID: 9412717
[No Abstract] [Full Text] [Related]
14. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
[TBL] [Abstract][Full Text] [Related]
16. Phase II/III Trials of Viracept start.
AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361632
[No Abstract] [Full Text] [Related]
17. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
Spear GT; Olinger G; Sullivan BL; Landay AL; Kessler H; Connick E; Kuritzkes D; St Clair M; Spritzler J; Wu H; Lederman MM
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1713-5. PubMed ID: 10606095
[No Abstract] [Full Text] [Related]
18. 144-week data released on Gilead's study 934.
AIDS Patient Care STDS; 2007 Aug; 21(8):603-4. PubMed ID: 17902243
[No Abstract] [Full Text] [Related]
19. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
Giaquinto C; De Romeo A; Giacomet V; Rampon O; Ruga E; Burlina A; De Rossi A; Sturkenboom M; D'Elia R
AIDS; 2001 May; 15(8):1074-5. PubMed ID: 11399997
[No Abstract] [Full Text] [Related]
20. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
